

BIONIME CORPORATION

ISIN Code: **TW0004737002**

Generated Date: 2026/06/05

Biotechnology and Medical Care


54.0 ▼ **0.2** High 54.6 | Low 53.0

【+/-/X represent Up/Down/Not compared】

Company Information

| | |
|---------------------|---|
| Company Name | BIONIME CORPORATION |
| Spokesman | ROY HUANG |
| Website | www.bionime.com |
| Capital | NT 772,852,530 |
| Main Business | <p>Bionime established in April 2003, BIONIME engages in the leading business of biotechnology and medical testing. Concerning medical testing, it can be further categorized into reagent and testing equipment. The product invested in and developed by BIONIME is a “blood glucose monitor and glucose strip,” which combines the fields of reagent and medical equipment. Employing the advantages of the R&D & manufacturing of electronics in Taiwan and the exquisite design in Switzerland, BIONIME integrates expertise in biochemistry, medicine and electronics, to manufacture products with smart applications. At BIONIME , we are committed to developing bio-sensors. Indeed, we are dedicated to developing innovative BIO -sensors by applying Nanotechnology in the modification of either Injection Molding Electrodes or Insertion Modified Electrodes — the heart of BIONIME biosensors.</p> |
| Listing Date | 2010/12/23 |
| Industry | Biotechnology and Medical Care |
| Investor Conference | WebPro link |


Price and Trade Information



| Date | Closing Price | Trade Volume | Date | Closing Price | Trade Volume | Date | Closing Price | Trade Volume |
|------|---------------|--------------|------|---------------|--------------|------|---------------|--------------|
| 6/4 | 54.0 | 75,464 | 5/21 | 57.5 | 50,932 | 5/7 | 58.5 | 115,234 |
| 6/3 | 54.2 | 77,889 | 5/20 | 58.2 | 59,421 | 5/6 | 57.3 | 117,258 |
| 6/2 | 55.0 | 119,654 | 5/19 | 58.2 | 74,552 | 5/5 | 58.2 | 109,886 |
| 6/1 | 56.9 | 105,957 | 5/18 | 57.0 | 115,076 | 5/4 | 59.8 | 158,523 |
| 5/29 | 57.1 | 123,663 | 5/15 | 60.6 | 166,052 | 4/30 | 62.1 | 162,937 |
| 5/28 | 59.9 | 187,822 | 5/14 | 55.3 | 151,812 | 4/29 | 62.7 | 93,668 |
| 5/27 | 60.0 | 188,847 | 5/13 | 58.0 | 50,392 | 4/28 | 63.0 | 170,268 |
| 5/26 | 58.5 | 99,767 | 5/12 | 58.2 | 107,233 | 4/27 | 60.0 | 138,223 |
| 5/25 | 56.3 | 139,251 | 5/11 | 59.4 | 86,869 | 4/24 | 61.8 | 91,694 |
| 5/22 | 57.0 | 47,769 | 5/8 | 58.8 | 124,629 | 4/23 | 62.2 | 200,728 |

Historical Trading Information

Securities Investment Trust Companies



Foreign Investors



Dealers




| Date | Securities Investment Trust Companies Difference(+)/(-) | Dealers Difference(+)/(-) | Foreign Investors Difference(+)/(-) | Date | Securities Investment Trust Companies Difference(+)/(-) | Dealers Difference(+)/(-) | Foreign Investors Difference(+)/(-) |
|------|--|------------------------------|--|------|--|------------------------------|--|
| 6/4 | 0 | +2,020 | +8,000 | 5/14 | 0 | -1,000 | -35,984 |
| 6/3 | 0 | -2,000 | -21,000 | 5/13 | 0 | -999 | -18,000 |
| 6/2 | 0 | -1,000 | -7,080 | 5/12 | 0 | 0 | +2,000 |
| 6/1 | 0 | -1,000 | +10,001 | 5/11 | 0 | 0 | +7,000 |
| 5/29 | 0 | 0 | +4,861 | 5/8 | 0 | 0 | +43,000 |
| 5/28 | 0 | +2,000 | -17,530 | 5/7 | 0 | +1,000 | +40,000 |
| 5/27 | 0 | -1,000 | +12,010 | 5/6 | 0 | -1,000 | +20,000 |
| 5/26 | 0 | 0 | -3,000 | 5/5 | 0 | -103 | +32,000 |
| 5/25 | 0 | -3,000 | +17,000 | 5/4 | 0 | +2,000 | -16,000 |
| 5/22 | 0 | -1,000 | -7,000 | 4/30 | 0 | +1,000 | -8,000 |
| 5/21 | 0 | +4,000 | -17,000 | 4/29 | 0 | -3,000 | +9,000 |
| 5/20 | 0 | +2,000 | -9,880 | 4/28 | 0 | 0 | +3,000 |
| 5/19 | 0 | +1,001 | -12,683 | 4/27 | 0 | 0 | -66,006 |
| 5/18 | 0 | 0 | -74,000 | 4/24 | 0 | 0 | +45,000 |
| 5/15 | 0 | -1,000 | -27,000 | 4/23 | 0 | -3,000 | +83,000 |

Purchase on Margin




Short Sale




| Date | Purchase on Margin | Short Sale | Date | Purchase on Margin | Short Sale | Date | Purchase on Margin | Short Sale |
|------|--------------------|------------|------|--------------------|------------|------|--------------------|------------|
| 6/4 | +16 | 0 | 5/21 | +4 | 0 | 5/7 | -16 | 0 |
| 6/3 | +1 | 0 | 5/20 | +19 | 0 | 5/6 | -12 | 0 |
| 6/2 | +4 | 0 | 5/19 | -2 | 0 | 5/5 | -61 | 0 |
| 6/1 | +50 | 0 | 5/18 | +17 | -2 | 5/4 | +3 | 0 |
| 5/29 | +11 | 0 | 5/15 | -58 | +2 | 4/30 | -24 | 0 |
| 5/28 | +34 | 0 | 5/14 | -44 | 0 | 4/29 | -12 | 0 |
| 5/27 | +93 | 0 | 5/13 | -6 | 0 | 4/28 | +34 | 0 |
| 5/26 | +51 | 0 | 5/12 | -7 | 0 | 4/27 | +38 | 0 |
| 5/25 | +11 | 0 | 5/11 | +1 | 0 | 4/24 | -10 | 0 |
| 5/22 | +2 | 0 | 5/8 | -56 | 0 | 4/23 | -49 | 0 |

Company Financials

EPS




Income from continuing operations before tax




| Quarter | Jan-Mar | | Jan-Jun | | Jan-Sep | | Jan-Dec | |
|---------|---------|---|---------|---|---------|---|---------|---|
| | EPS | Income from continuing operations before tax (Thousand) | EPS | Income from continuing operations before tax (Thousand) | EPS | Income from continuing operations before tax (Thousand) | EPS | Income from continuing operations before tax (Thousand) |
| 2026 | -1.09 | -100,891 | - | - | - | - | - | - |
| 2025 | -0.21 | -15,219 | -0.45 | -37,109 | -1.31 | -131,578 | -2.68 | -249,405 |
| 2024 | -0.08 | -13,098 | -0.67 | -66,145 | -1.55 | -137,736 | -2.09 | -185,711 |
| 2023 | -0.09 | -15,565 | 0.08 | 7,566 | -0.09 | -5,478 | 0.10 | -31,875 |
| 2022 | 0.23 | 7,954 | 0.88 | 54,831 | 1.05 | 64,997 | 1.50 | 86,483 |
| 2021 | 0.20 | 9,222 | 0.42 | 18,038 | 0.93 | 47,333 | 1.45 | 74,585 |

Monthly Revenue



| Monthly | Monthly Revenue | Monthly | Monthly Revenue | Monthly | Monthly Revenue | Monthly | Monthly Revenue | Monthly | Monthly Revenue |
|---------|-----------------|---------|-----------------|---------|-----------------|---------|-----------------|---------|-----------------|
| 2026/04 | 141,322,000 | 2025/04 | 154,331,000 | 2024/04 | 137,303,000 | 2023/04 | 88,096,000 | 2022/04 | 175,027,000 |
| 2026/03 | 167,488,000 | 2025/03 | 159,902,000 | 2024/03 | 177,098,000 | 2023/03 | 141,601,000 | 2022/03 | 259,364,000 |
| 2026/02 | 110,554,000 | 2025/02 | 155,592,000 | 2024/02 | 140,298,000 | 2023/02 | 150,250,000 | 2022/02 | 115,287,000 |
| 2026/01 | 127,221,000 | 2025/01 | 165,946,000 | 2024/01 | 151,078,000 | 2023/01 | 123,272,000 | 2022/01 | 100,995,000 |
| 2025/12 | 160,880,000 | 2024/12 | 142,633,000 | 2023/12 | 180,598,000 | 2022/12 | 186,148,000 | 2021/12 | 180,301,000 |
| 2025/11 | 128,734,000 | 2024/11 | 181,610,000 | 2023/11 | 132,608,000 | 2022/11 | 183,793,000 | 2021/11 | 150,125,000 |
| 2025/10 | 137,348,000 | 2024/10 | 177,974,000 | 2023/10 | 176,451,000 | 2022/10 | 226,694,000 | 2021/10 | 147,234,000 |
| 2025/09 | 148,936,000 | 2024/09 | 162,080,000 | 2023/09 | 128,176,000 | 2022/09 | 255,740,000 | 2021/09 | 185,323,000 |
| 2025/08 | 167,241,000 | 2024/08 | 166,956,000 | 2023/08 | 121,393,000 | 2022/08 | 144,384,000 | 2021/08 | 148,344,000 |
| 2025/07 | 142,322,000 | 2024/07 | 159,235,000 | 2023/07 | 175,574,000 | 2022/07 | 164,715,000 | 2021/07 | 162,210,000 |
| 2025/06 | 153,628,000 | 2024/06 | 170,225,000 | 2023/06 | 182,675,000 | 2022/06 | 259,327,000 | 2021/06 | 155,828,000 |
| 2025/05 | 163,726,000 | 2024/05 | 167,256,000 | 2023/05 | 154,875,000 | 2022/05 | 138,974,000 | 2021/05 | 126,419,000 |

PE ratio



| Date | PE ratio | Date | PE ratio | Date | PE ratio |
|------|----------|------|----------|------|----------|
| 6/4 | 0.00 | 5/21 | 0.00 | 5/7 | 0.00 |
| 6/3 | 0.00 | 5/20 | 0.00 | 5/6 | 0.00 |
| 6/2 | 0.00 | 5/19 | 0.00 | 5/5 | 0.00 |
| 6/1 | 0.00 | 5/18 | 0.00 | 5/4 | 0.00 |
| 5/29 | 0.00 | 5/15 | 0.00 | 4/30 | 0.00 |
| 5/28 | 0.00 | 5/14 | 0.00 | 4/29 | 0.00 |
| 5/27 | 0.00 | 5/13 | 0.00 | 4/28 | 0.00 |
| 5/26 | 0.00 | 5/12 | 0.00 | 4/27 | 0.00 |
| 5/25 | 0.00 | 5/11 | 0.00 | 4/24 | 0.00 |
| 5/22 | 0.00 | 5/8 | 0.00 | 4/23 | 0.00 |

Announcements

(Please refer to [mops](#) for the most updated information)

| Subject | Date |
|---|---------------------|
| ▶ The Company's 2026 first quarter consolidated financial statements have been approved by the Board of Directors. | 2026/05/13 16:05:52 |
| ▶ Announcement of TFDA Class II Medical Device Approval for the Company's RIGHTEST iFree2 CGM. | 2026/04/29 17:45:28 |
| ▶ The Company's 2025 consolidated financial statements have been approved by the Board of Directors. | 2026/03/11 17:30:33 |
| ▶ Announcement of the Board of Directors' Resolution Not to Distribute Dividends. | 2026/03/11 17:32:49 |
| ▶ Announcement of the Expiration of the Collection Period for Capital Increase by Cash and Matters Related to Share Delivery. | 2026/03/04 18:15:04 |

Corporate Action

| Year | Shareholders' meeting date | Period | Cash dividends | Stock dividends |
|------|----------------------------|--------|----------------|-----------------|
| 2025 | - | 2025 | 0.00000 | 0.00000 |
| 2024 | 2025/06/17 | 2024 | 0.00000 | 0.00000 |
| 2023 | - | 2023 | 0.09500 | 0.00000 |
| 2022 | - | 2022 | 0.38000 | 0.00000 |
| 2021 | - | 2021 | 1.25000 | 0.00000 |